mastl Antibody

What is MASTL and what are its primary functions in cellular processes?

MASTL is a ubiquitous microtubule-associated serine/threonine kinase that plays a critical role in mitotic progression. During mitotic entry, CDK1 and MASTL kinase repress the activity of mitotic protein phosphatases PP1 and PP2A. For mitotic exit to occur, MASTL requires partial dephosphorylation by PP1, followed by dephosphorylation of PP2A . This regulated sequence is essential for proper cell division.

Beyond its canonical role in mitosis, MASTL has emerged as a key player in cancer progression and stemness maintenance. It is significantly enriched in pluripotent stem cells and breast cancer stem cells, where it supports stemness regulators such as OCT1, OCT4, and NANOG . MASTL also regulates the TGF-β signaling pathway through modulation of TGFBR2 expression .

How is MASTL expression regulated in normal versus cancer tissues?

• Triple-negative breast cancer (TNBC) phenotype

• ER-negative, HER2-negative receptor subtypes

• High histological grade and poor differentiation

• Basal-like breast cancer subtype

• Ki-67 positivity

The significant association between MASTL expression and cancer progression suggests a selective advantage for cancer cells with high MASTL levels. In oral squamous cell carcinoma (OSCC), higher MASTL expression correlates with poor survival outcomes in patients .

What are the common challenges in detecting MASTL protein in different experimental systems?

Detecting MASTL presents several challenges that researchers should be aware of:

• Subcellular localization complexity: MASTL shows both nuclear and cytoplasmic expression patterns depending on cell type and cell cycle phase. In interphase cells, MASTL localizes primarily to nuclei before nuclear envelope breakdown .

• Expression level variations: MASTL expression can vary significantly across tissue types and experimental models, requiring optimization of antibody dilutions for each system.

• Specificity concerns: Some commercial antibodies may cross-react with related kinases. Validation using MASTL-depleted samples (via siRNA) is recommended to confirm antibody specificity .

• Phosphorylation status: MASTL undergoes multiple phosphorylation events that can affect antibody binding. Researchers should consider whether their antibody recognizes specific phosphorylated forms or total MASTL protein .

What criteria should researchers use when selecting a MASTL antibody for specific applications?

When selecting a MASTL antibody, researchers should consider:

• Application compatibility: Confirm that the antibody has been validated for your specific application (Western blot, immunohistochemistry, immunofluorescence, etc.). Different antibodies may perform optimally in different applications.

• Species reactivity: Ensure the antibody recognizes MASTL from your species of interest. Many MASTL antibodies are developed against human MASTL, but cross-reactivity with mouse or rat MASTL should be verified if working with these models.

• Epitope location: Consider whether the epitope is in a domain that might be affected by protein interactions or post-translational modifications relevant to your research question.

• Monoclonal vs. polyclonal: Monoclonal antibodies offer higher specificity but may be limited in epitope recognition, while polyclonal antibodies provide broader detection but potentially more background.

• Published validation: Prioritize antibodies with published validation data, especially those used in peer-reviewed publications studying MASTL in contexts similar to your research.

How can researchers validate the specificity of MASTL antibodies in their experimental systems?

Proper validation of MASTL antibodies is crucial for reliable results. Recommended validation approaches include:

• Genetic knockdown/knockout controls: Use siRNA/shRNA knockdown or CRISPR/Cas9 knockout of MASTL to confirm specificity. A specific antibody should show reduced or absent signal in depleted samples .

• Overexpression controls: Complementary to knockdown, overexpression of tagged MASTL can confirm antibody recognition of the target protein.

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should block specific binding.

• Multiple antibody comparison: Using antibodies raised against different MASTL epitopes can increase confidence in the specificity of detected signals.

• Cross-species reactivity confirmation: If working across species, confirm specificity in each species used in your experiments.

What are the optimal fixation and antigen retrieval methods for MASTL immunohistochemistry?

For optimal MASTL detection in tissue sections:

• Fixation: 10% neutral buffered formalin fixation for 24-48 hours is generally effective for preserving MASTL epitopes. Overfixation should be avoided as it can mask epitopes.

• Antigen retrieval methods: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) has been successfully used in MASTL immunohistochemistry studies. For some antibodies, EDTA buffer (pH 9.0) may provide better results.

• Protocol optimization: Researchers should optimize retrieval time and temperature based on their specific tissue type and antibody. Starting parameters typically include:

  • 20 minutes of pressure cooking

  • or 95-98°C water bath treatment for 30-40 minutes

• Controls: Always include positive control tissues with known MASTL expression (e.g., proliferating mammary tissue or breast cancer samples) and negative controls (antibody diluent only) .

What are the recommended protocols for detecting MASTL in cancer stem cells?

Detecting MASTL in cancer stem cells requires special considerations due to their unique properties:

• Sample preparation:

  • For mammosphere cultures: Grow cells in low-attachment plates with serum-free media supplemented with B27, EGF, and bFGF to enrich for stem-like cells .

  • Process spheres carefully to avoid loss during centrifugation steps.

• Detection methods:

  • Flow cytometry: For co-detection of MASTL with stem cell markers (CD44+/CD24-), use fixation and permeabilization protocols compatible with intracellular staining. Consider dual staining with stemness markers like OCT1.

  • Immunofluorescence: Fix mammospheres with 4% paraformaldehyde, embed in OCT compound, and section before staining to preserve 3D structure.

  • Western blotting: When comparing monolayer and sphere cultures, normalize loading carefully using housekeeping proteins stable across these conditions.

• Controls and validation:

  • Use parallel detection of established stemness markers (ITGB3, OCT1, CD44) as positive controls .

  • Verify enrichment by evaluating stemness marker expression before MASTL analysis.

How should researchers quantify MASTL expression in tissue microarrays for correlation with clinical outcomes?

For quantitative assessment of MASTL in tissue microarrays:

• Scoring systems:

  • Implement a scoring system that captures both staining intensity and percentage of positive cells, such as the H-score (0-300) or Allred score (0-8).

  • Alternatively, use digital image analysis software for more objective quantification.

• Standardization:

  • Include reference standards on each TMA slide to normalize between batches.

  • Blind scoring by multiple pathologists improves reliability.

• Subcellular localization:

  • Score nuclear and cytoplasmic staining separately, as MASTL shows both patterns .

  • Consider developing a combined score that weights these compartments based on biological relevance.

• Statistical analysis:

  • Use appropriate statistical methods to correlate MASTL expression with clinical parameters:

    • Kaplan-Meier survival analysis with log-rank tests for survival outcomes

    • Chi-square or Fisher's exact tests for association with categorical variables

    • Multivariate Cox regression to assess independent prognostic value

Studies have shown that high MASTL expression correlates with poor patient survival in oral cancer, suggesting its potential as a prognostic biomarker .

What protocols are recommended for studying the MASTL-ENSA-PP2A/B55 signaling axis in drug resistance models?

The MASTL-ENSA-PP2A/B55 pathway has been implicated in cisplatin resistance in cancer cells. To study this axis:

• Pathway component detection:

  • Use validated antibodies against MASTL, ENSA/ARPP19, and PP2A/B55 subunits.

  • Consider phospho-specific antibodies to detect the active forms of these proteins.

• Functional perturbation approaches:

  • siRNA knockdown of individual components (MASTL, ENSA) to assess their contribution to drug resistance .

  • Small molecule inhibitors like GKI-1 can be used to pharmacologically target the pathway .

  • For rescue experiments, use expression vectors containing wild-type or mutant forms of pathway components.

• Resistance assessment protocols:

  • Cell viability assays with dose-response curves to determine IC50 values for cisplatin.

  • Colony formation assays to assess long-term survival.

  • Soft agar growth assays to evaluate anchorage-independent growth .

• Mechanism investigation:

  • Western blotting for DNA damage response markers (phospho-CHK2, cleaved caspase-3, PARP1) .

  • Flow cytometry for cell cycle analysis and apoptosis quantification.

Data from these experiments can reveal how modulation of the MASTL pathway affects drug sensitivity, as demonstrated in OSCC cells where MASTL overexpression conferred cisplatin resistance through an ENSA-dependent mechanism .

How can researchers investigate the relationship between MASTL and stemness in pluripotent and cancer stem cells?

Investigating MASTL's role in stemness requires sophisticated approaches:

• Co-expression analysis techniques:

  • Multiplex immunofluorescence to simultaneously detect MASTL with stemness markers (OCT4, NANOG, SOX2).

  • Single-cell RNA-seq combined with protein detection to correlate MASTL expression with stemness signatures at the single-cell level.

• Functional assessment of stemness:

  • Sphere formation assays before and after MASTL manipulation to quantify self-renewal capacity.

  • In vivo limiting dilution assays to evaluate tumor-initiating capacity of MASTL-high versus MASTL-low cells.

  • Differentiation induction protocols to assess whether MASTL knockdown accelerates loss of pluripotency .

• Mechanistic investigations:

  • Chromatin immunoprecipitation (ChIP) to identify potential direct regulation of stemness genes by MASTL.

  • Proteomics approaches like SILAC to identify MASTL-dependent changes in the stem cell proteome .

  • Proximity labeling methods (BioID, APEX) to identify MASTL interactors in stem cell contexts.

Research has shown that MASTL expression is significantly higher in pluripotent stem cells compared to differentiated cells and decreases upon differentiation to any lineage . Additionally, MASTL silencing reduces expression of key pluripotency factors like OCT4 and NANOG .

What are the approaches to study MASTL phosphorylation dynamics during the cell cycle and in response to DNA damage?

Studying MASTL phosphorylation dynamics requires specialized techniques:

• Temporal resolution methods:

  • Synchronize cells at different cell cycle phases using techniques like double thymidine block or nocodazole arrest.

  • Use Phos-tag SDS-PAGE to enhance mobility shifts of phosphorylated MASTL forms.

  • Employ phospho-specific antibodies targeting key sites like the turn motif phosphosite (S861) .

• Mass spectrometry approaches:

  • Stable isotope labeling with amino acids in cell culture (SILAC) combined with phosphopeptide enrichment.

  • Parallel reaction monitoring (PRM) for targeted quantification of specific MASTL phosphopeptides.

  • Phosphoproteomics after DNA damage induction to capture dynamic changes.

• Live-cell imaging:

  • Generate cell lines expressing MASTL phosphorylation sensors based on FRET technology.

  • Combine with cell cycle phase markers to correlate phosphorylation with specific cell cycle transitions.

Research has revealed that phosphorylation of the turn motif phosphosite (S861) is auxiliary and not indispensable for MASTL function , highlighting the complexity of MASTL regulation.

How can researchers investigate the role of MASTL in regulating the TGF-β signaling pathway in cancer models?

MASTL has been linked to TGF-β signaling through regulation of TGFBR2. To study this connection:

• Pathway component assessment:

  • Use validated antibodies to detect TGFBR2 expression and localization after MASTL manipulation.

  • Examine downstream pathway activation by assessing phosphorylation of SMAD3 and AKT .

• Functional signaling assays:

  • SMAD reporter assays (using constructs like SBE4-Luc) to quantify pathway activity.

  • TGF-β-responsive gene expression analysis via qRT-PCR or RNA-seq.

  • Rescue experiments using TGFBR2 overexpression in MASTL-depleted cells.

• Cell surface proteomics:

  • SILAC-based cell surface biotinylation followed by mass spectrometry to identify MASTL-dependent changes in the surfaceome .

  • Flow cytometry to quantify cell surface TGFBR2 levels in response to MASTL manipulation.

• Mechanistic investigations:

  • Inhibitor studies to determine whether MASTL's effect on TGF-β signaling is kinase-dependent.

  • Co-immunoprecipitation to identify potential physical interactions between MASTL and TGF-β pathway components.

Research has shown that MASTL silencing attenuates TGFBR2 levels and downstream signaling through SMAD3 and AKT pathways, while MASTL overexpression elevates TGFBR2 levels .

What are the common causes of false positive or negative results when using MASTL antibodies?

Researchers may encounter several issues when using MASTL antibodies:

False Positive Results:

• Cross-reactivity: Some antibodies may detect related kinases with similar epitopes.

• Non-specific binding: Particularly problematic in immunohistochemistry and immunofluorescence applications.

• Background from secondary antibodies: Can occur if blocking is insufficient or if secondary antibody concentration is too high.

• Endogenous peroxidase activity: In IHC, incomplete quenching of endogenous peroxidases can lead to false signals.

False Negative Results:

• Epitope masking: Post-translational modifications or protein interactions may block antibody binding sites.

• Inadequate antigen retrieval: Critical for formalin-fixed tissues where crosslinking can mask epitopes.

• Protein degradation: MASTL may be sensitive to degradation during sample preparation.

• Low expression levels: In some tissues or conditions, MASTL expression may be below detection threshold.

Troubleshooting Strategies:

• Include proper controls: Both positive controls (known MASTL-expressing samples) and negative controls (MASTL-depleted samples).

• Validate with multiple techniques: Confirm findings using orthogonal methods (e.g., western blot and immunofluorescence).

• Titrate antibody concentration: Optimize signal-to-noise ratio through careful titration experiments.

• Modify lysis conditions: For western blotting, test different lysis buffers that may better preserve MASTL structure or disrupt interfering interactions.

How should researchers interpret contradictory results between different MASTL detection methods?

When faced with contradictory results between different detection methods:

• Consider method-specific limitations:

  • Western blotting may not detect all isoforms or post-translational modifications.

  • IHC results can be influenced by tissue processing and antigen retrieval methods.

  • IF may show altered localization patterns due to fixation artifacts.

• Evaluate antibody characteristics:

  • Different antibodies may recognize distinct epitopes that are differentially accessible in various methods.

  • Check if antibodies detect total MASTL or specific phosphorylated forms.

• Resolution approaches:

  • Use genetic approaches (siRNA, CRISPR) to validate specificity across methods.

  • Consider alternative antibodies that target different epitopes.

  • Employ tagged MASTL constructs as reference standards across methods.

  • Use mass spectrometry-based approaches as an antibody-independent validation.

• Data integration strategy:

  • Weight results based on the robustness of each method's controls.

  • Consider biological context – some discrepancies may reflect genuine biological differences rather than technical artifacts.

  • Report all findings transparently in publications, acknowledging limitations of each approach.

What are the best practices for quantitative analysis of MASTL expression across different experimental systems?

For reliable quantitative analysis of MASTL:

• Standardization across experiments:

  • Use consistent antibody lots, concentrations, and protocols.

  • Include reference standards on each blot/slide for inter-experiment normalization.

  • Process all comparative samples simultaneously when possible.

• Western blot quantification:

  • Use validated housekeeping proteins appropriate for your experimental conditions.

  • Ensure signal is within linear detection range of imaging system.

  • Consider Stain-Free technology or total protein normalization as alternatives to housekeeping proteins.

• Immunohistochemistry quantification:

  • Use digital image analysis with validated algorithms for objective scoring.

  • Standardize image acquisition parameters (exposure, white balance, etc.).

  • Consider multiplexed approaches to normalize to cell number in heterogeneous tissues.

• Flow cytometry approaches:

  • Use isotype controls and fluorescence-minus-one (FMO) controls.

  • Report data as median fluorescence intensity (MFI) rather than percent positive when appropriate.

  • Use bead standards for day-to-day normalization.

• Statistical analysis considerations:

  • Account for batch effects using appropriate statistical models.

  • Use non-parametric tests when normality cannot be assumed.

  • Include power analyses to ensure sufficient sample sizes for detecting biologically meaningful differences.